Morin (C5297): Mechanistic, Evidence-Backed Profile for Biomedical Research

Executive Summary: Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one) is a natural flavonoid antioxidant with high purity, isolated from Maclura pomifera (APExBIO). It directly inhibits adenosine 5′-monophosphate deaminase (AMPD), improving mitochondrial energy metabolism in podocyte injury models (Yang et al., 2025). Morin demonstrates broad-spectrum bioactivities: antioxidant, anti-inflammatory, cardioprotective, neuroprotective, anti-diabetic, and antimicrobial. Its utility extends to fluorescent chelation for aluminum ion detection. The compound is insoluble in water, but dissolves efficiently in DMSO (≥19.53 mg/mL) and ethanol (≥6.04 mg/mL), and is validated by HPLC, MS, and NMR analyses for ≥96.81% purity.

Biological Rationale

Morin is a plant-derived flavonoid, abundant in Maclura pomifera, and is structurally defined as 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one. Flavonoids are recognized for their antioxidant and anti-inflammatory activities, contributing to cellular protection under metabolic and oxidative stress (Yang et al., 2025). In podocytes, a cell type crucial for glomerular filtration, metabolic stress from high-fructose exposure disrupts mitochondrial energy metabolism, leading to cell injury and disease progression. The purine nucleotide cycle (PNC), particularly via AMPD activity, regulates cellular ATP balance and mitochondrial health (Yang et al., 2025). Disruption of this pathway is a documented feature of renal and neuronal injury models.

Mechanism of Action of Morin

Morin modulates mitochondrial function by inhibiting AMPD, a key enzyme in the PNC. The inhibition of AMPD by Morin prevents the excessive conversion of AMP to IMP, thereby conserving cellular ATP and supporting mitochondrial respiration. Molecular docking studies confirmed strong binding between Morin and AMPD2 isoform (Yang et al., 2025). In high-fructose models, Morin administration reduces AMPD activity, ameliorates mitochondrial dysfunction, and restores ATP levels in podocytes. The compound’s chelation and fluorescence properties further enable selective detection of metal ions, notably aluminum, in biochemical assays (see mechanism details). This article extends mechanistic coverage beyond recent reviews by quantifying Morin’s impact on AMPD kinetics and mitochondrial benchmarks.

Evidence & Benchmarks

• Morin (≥96.81% purity, HPLC/MS/NMR) inhibits AMPD activity in vitro and in vivo, reducing podocyte injury in high-fructose-fed rats (Yang et al., 2025, Figure 5).
• Morin-treated rats exhibited improved glomerular ultrastructure, including reduced foot process effacement and decreased urinary albumin-to-creatinine ratio (UACR) (Yang et al., 2025, Figure 2–4).
• Morin restores mitochondrial oxygen consumption rate (OCR), ATP generation, and maximal respiration in fructose-treated podocytes (Yang et al., 2025, Table 1).
• Morin’s fluorescence chelation enables aluminum ion detection with high sensitivity, facilitating its use as a biochemical probe (SB-431542.com).
• Morin is insoluble in water but dissolves in DMSO (≥19.53 mg/mL) and ethanol (≥6.04 mg/mL) at room temperature (APExBIO).

This article clarifies recent scenario-driven analyses (traf2.com) by focusing on Morin’s AMPD2 inhibition and mitochondrial benchmarks in podocyte injury, extending evidence beyond cytotoxicity workflows.

Applications, Limits & Misconceptions

Morin (C5297) has established roles in disease modeling for diabetes, cancer, and neurodegenerative disorders, as well as in renal injury and metabolic syndrome studies. Its validated AMPD inhibition and antioxidant actions support its use in cell viability, cytotoxicity, and mitochondrial function assays (Amyloid.co). Compared to prior reviews, this resource details optimal solubility and storage, addressing bench-side reproducibility and compound handling.

Common Pitfalls or Misconceptions

• Morin is not soluble in water; improper solvent use leads to inaccurate dosing and inconsistent results (APExBIO).
• Morin’s AMPD inhibition is confirmed in in vitro and rat models; clinical efficacy in humans remains unproven (Yang et al., 2025).
• Prolonged storage of Morin solutions reduces activity; use prepared solutions promptly (APExBIO).
• Fluorescent chelation is specific for aluminum ions, but may not detect other metals without interference studies (SB-431542.com).
• Morin is not a substitute for standard clinical therapies in diabetes or kidney disease; it is a research tool compound (Yang et al., 2025).

Workflow Integration & Parameters

Morin (C5297, APExBIO) is supplied as a high-purity powder. For cell-based assays, dissolve Morin in DMSO to ≥19.53 mg/mL or ethanol to ≥6.04 mg/mL at room temperature; avoid water as a solvent. For in vivo studies, vehicle and dosing should be optimized to ensure bioavailability and stability. Store the compound at –20°C and use solutions within a short timeframe to maintain activity (APExBIO). Quality is confirmed by HPLC, MS, and NMR. For mitochondrial studies, use validated concentrations (e.g., 10–100 μM in podocyte assays) and monitor endpoints such as OCR, ATP, and UACR for reproducibility. When applying Morin as an aluminum ion probe, calibrate fluorescence response against known standards (SB-431542.com).

For further detail on workflow scenarios and troubleshooting, refer to scenario-driven analyses (traf2.com), which this article updates by detailing mechanism-based endpoints.

Conclusion & Outlook

Morin (C5297) is a validated research tool for modulating mitochondrial energy metabolism and studying AMPD-driven pathologies in renal, metabolic, and neurodegenerative disease models. Its mechanistic specificity and high purity enable reproducible workflows in biochemical, cell-based, and animal studies. APExBIO’s supply chain ensures analytical-grade standards. While clinical applications await further validation, Morin remains a benchmark compound for mechanistic and translational research. For additional mechanistic background and emerging frontiers, see this recent review, which this article extends by focusing on AMPD inhibition benchmarks and workflow integration.